Somerville Kurt F Has $763,000 Holdings in Eli Lilly And Co (LLY)

Somerville Kurt F decreased its stake in Eli Lilly And Co (NYSE:LLY) by 4.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 5,880 shares of the company’s stock after selling 275 shares during the period. Somerville Kurt F’s holdings in Eli Lilly And Co were worth $763,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc boosted its holdings in shares of Eli Lilly And Co by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock worth $7,955,211,000 after buying an additional 511,752 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Eli Lilly And Co by 2.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 21,046 shares of the company’s stock worth $2,435,000 after buying an additional 475 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its holdings in shares of Eli Lilly And Co by 87.0% during the 4th quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 78,314 shares of the company’s stock worth $9,062,000 after buying an additional 36,425 shares in the last quarter. Personal Capital Advisors Corp boosted its holdings in shares of Eli Lilly And Co by 32.8% during the 4th quarter. Personal Capital Advisors Corp now owns 17,642 shares of the company’s stock worth $2,042,000 after buying an additional 4,358 shares in the last quarter. Finally, Boston Advisors LLC boosted its holdings in shares of Eli Lilly And Co by 2.3% during the 4th quarter. Boston Advisors LLC now owns 98,546 shares of the company’s stock worth $11,404,000 after buying an additional 2,173 shares in the last quarter. Institutional investors and hedge funds own 84.49% of the company’s stock.

In related news, SVP Aarti S. Shah sold 1,800 shares of Eli Lilly And Co stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $125.85, for a total value of $226,530.00. Following the completion of the sale, the senior vice president now owns 18,425 shares of the company’s stock, valued at approximately $2,318,786.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the transaction, the insider now owns 117,641,684 shares of the company’s stock, valued at approximately $14,408,753,456.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 845,959 shares of company stock valued at $106,647,752. Insiders own 0.11% of the company’s stock.

Shares of Eli Lilly And Co stock opened at $116.73 on Friday. Eli Lilly And Co has a 1 year low of $81.03 and a 1 year high of $132.13. The firm has a market cap of $112.25 billion, a PE ratio of 21.03, a price-to-earnings-growth ratio of 2.05 and a beta of 0.27. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. During the same period last year, the firm posted $1.31 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Equities analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be given a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.21%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

A number of research firms have issued reports on LLY. Credit Suisse Group set a $121.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday, March 22nd. Bank of America set a $129.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a report on Thursday, March 21st. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a research note on Wednesday, April 10th. Guggenheim cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective on the stock. in a research note on Thursday, April 11th. Finally, UBS Group initiated coverage on Eli Lilly And Co in a research note on Wednesday, March 20th. They set a “buy” rating and a $74.51 price objective on the stock. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average target price of $118.15.

WARNING: This report was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/17/somerville-kurt-f-has-763000-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.